Skip to main content

Actuate Therapeutics, Inc.

corporate_fare Company Profile

Actuate Therapeutics, Inc.

ACTU·NASDAQ·Life Sciences·CIK 0001652935

The company is a clinical-stage biopharmaceutical company focused on developing therapies for high-impact, difficult-to-treat cancers. It achieves this through the inhibition of glycogen synthase kinase-3 ("GSK-3"). The company's primary product in development is elraglusib, an ATP-competitive small molecule designed to enter cancer cells and block the function of the enzyme glycogen synthase kinase-3 beta ("GSK-3β"). This enzyme is a master regulator of complex biological signaling cascades, including those mediated by oncogenes, which contribute to tumor cell survival, growth, migration, and invasion. The company believes that blocking GSK-3β signaling ultimately leads to the death of cancer cells and the regulation of anti-tumor immunity. There are no approved high-affinity inhibitors of GSK-3β, and elraglusib is considered one of the most advanced GSK-3β inhibitors in clinical development. Elraglusib was previously known as 9-ING-41 but received the elraglusib International Nonproprietary Names ("INN") and United States Adopted Names ("USAN") generic name in 2021. The company has exclusively licensed elraglusib, which is a proprietary and patent-protected GSK-3 inhibitor developed through a collaboration between The Board of Trustees of the University of Illinois-Chicago ("UIC") and Northwestern University ("NU"). Elraglusib is believed to have broad therapeutic potential, with evidence of preclinical and clinical activity observed in various cancer types, including pancreatic, metastatic melanoma, lung, colon, breast, renal, and ovarian cancer, leukemias and lymphomas, as well as pediatric cancers such as Ewing sarcoma, neuroblastoma, and pediatric leukemias.

Actuate Therapeutics, Inc. (NASDAQ:ACTU) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 26 items for ACTU at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Elraglusib Doubles Survival Rate in Pancreatic Cancer, Nature Medicine Publishes Pivotal Phase 2 Data
  • Actuate Therapeutics Faces Going Concern Despite Positive Phase 2 Data and Recent Capital Raises
  • Actuate Therapeutics Eyes $200M+ Pediatric PRV, Potentially Tripling Market Cap
  • Actuate Therapeutics Launches Strategic Research to Combine Elraglusib with RAS Inhibitors, Targeting Resistance in Cancers
  • Actuate Therapeutics Reports Positive Phase 2 Data for Elraglusib in Pancreatic Cancer, Showing Significant Overall Survival Benefit

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$22.23M
Diluted EPS
-$1.06
Op. Cash Flow
-$19.21M
Operating Income
-$22.5M
Cash & Equivalents
$13.16M
Debt / Equity
0.00×
Shares Outstanding
23.25M sh
Source: 10-K · filed 2026-03-26 · accession 0001683168-26-002257
$0.2004 -11.05% today
52-week range · as of 2026-11-13 $0.2004 – $7.9
Market cap
$13.6M
Volume
646.6K (0.5× avg)
3-mo avg 1.3M
Live data · 2026-11-22 12:47 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed ACTU - Filings & News (Page 2)

ACTU
Apr 14, 2026, 8:45 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $1.81
Real-time Price: $0.2004 info
Change: -$1.61 (-89%) info
Market Cap: $13.604M info
ACTU
Mar 26, 2026, 4:00 PM EDT
Filing Type: 10-K
Importance Score:
9
Price at Filing: $2.27
Real-time Price: $0.2004 info
Change: -$2.07 (-91%) info
Market Cap: $13.604M info
ACTU
Mar 24, 2026, 7:00 AM EDT
Source: Access Newswire
Importance Score:
9
Price at Filing: $2.44
Real-time Price: $0.2004 info
Change: -$2.24 (-92%) info
Market Cap: $13.604M info
ACTU
Mar 09, 2026, 8:45 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $2.84
Real-time Price: $0.2004 info
Change: -$2.64 (-93%) info
Market Cap: $13.604M info
ACTU
Jan 12, 2026, 4:00 PM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $5.81
Real-time Price: $0.2004 info
Change: -$5.61 (-97%) info
Market Cap: $13.604M info
ACTU
Jan 07, 2026, 12:45 PM EST
Filing Type: 4
Importance Score:
8
Price at Filing: $6.73
Real-time Price: $0.2004 info
Change: -$6.53 (-97%) info
Market Cap: $13.604M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets